Charles T. Saldarini
Charles T. Saldarini is a recognized expert in bio-pharmaceutical services and an acknowledged leader and innovator in the field of outsourcing.
Saldarini joined Sentrx in April 2009 as CEO, attracted by the company's strong record of performance, its highly experienced investor base, and a compelling core value proposition.
Between 2006 and 2009, Saldarini
founded and led The Charles T. Saldarini Group
, an independent consulting organization evaluating both emerging and commercial-stage companies in life sciences on behalf of investors seeking opportunities in commercial product development and service company expansion.
Prior to 2006, Saldarini spent eighteen years with PDI, Inc. (NASDAQ: PDII), where he was a major force in driving development of the outsourced contract sales industry.
He led PDI from its earliest stage, built its reputation as a premier provider, and drove its annual revenue growth from $1 M to $365 M. Throughout his tenure, he oversaw creation of all infrastructure, systems, and talent growth supporting an employee population of 3,000 and a world-class bio-pharmaceutical client base.
leadership enabled a successful public capitalization in 1998, followed by multiple acquisitions and strategic partnerships.
departure as Vice Chairman and CEO in 2005, PDI
was debt free, held over $100 M in cash and was well positioned as a complete commercial services provider.
Saldarini began his career as a sales representative for Merrill-Dow Pharmaceuticals.
He earned a bachelor of arts with honors in political science and telecommunications from Syracuse University.
Currently, he serves on the boards of Cadient Group , Octagon Clinical Research Solutions, and Informed Medical Communications.
Additionally, Saldarini is active in the field of education, serving on the Board of Visitors at Syracuse University, the Board of Advisors at Anisfield School of Business at Ramapo College, and his local school board.